Literature DB >> 20648590

Adjuvant external beam radiation for medullary thyroid carcinoma.

Steve R Martinez1, Shannon H Beal, Allen Chen, Steven L Chen, Philip D Schneider.   

Abstract

BACKGROUND: Adjuvant radiation is rarely used to treat medullary thyroid carcinoma (MTC). We hypothesized that external beam radiation therapy (EBRT) would improve overall survival (OS) in MTC patients.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database identified patients who underwent total thyroidectomy and lymph nodes excision for MTC between 1988 and 2004. The Kaplan-Meier method was used for univariate comparisons of OS. Multivariate Cox proportional hazards models controlled for gender, age, lymph node status, tumor size, extent of disease, and EBRT.
RESULTS: After 12 years, EBRT did not significantly improve OS (log rank, P < 0.14). In node-positive patients, univariate analysis demonstrated an OS benefit with EBRT (log rank, P < 0.05). In a multivariate model of node-positive patients, only increasing age (P < 0.001) and tumor size (P < 0.001) significantly influenced OS.
CONCLUSIONS: The OS benefit attributed to EBRT in node-positive patients by univariate analysis could not be duplicated when controlling for known prognostic factors. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20648590      PMCID: PMC2908956          DOI: 10.1002/jso.21557

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  24 in total

1.  Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era.

Authors:  David L Schwartz; Vishal Rana; Stephanie Shaw; Cynthia Yazbeck; Kie-Kian Ang; William H Morrison; David I Rosenthal; Ana Hoff; Douglas B Evans; Gary L Clayman; Adam S Garden; Steven I Sherman
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

2.  Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course.

Authors:  S Leboulleux; J P Travagli; B Caillou; A Laplanche; J M Bidart; M Schlumberger; E Baudin
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

3.  Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy.

Authors:  N A Samaan; P N Schultz; R C Hickey
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

4.  Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control.

Authors:  J Brierley; R Tsang; W J Simpson; M Gospodarowicz; S Sutcliffe; T Panzarella
Journal:  Thyroid       Date:  1996-08       Impact factor: 6.568

5.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.

Authors:  S A Hundahl; B Cady; M P Cunningham; E Mazzaferri; R F McKee; J Rosai; J P Shah; A M Fremgen; A K Stewart; S Hölzer
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

6.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.

Authors:  Neil Bhattacharyya
Journal:  Otolaryngol Head Neck Surg       Date:  2003-01       Impact factor: 3.497

8.  Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma.

Authors:  A Miyauchi; T Onishi; S Morimoto; S Takai; F Matsuzuka; K Kuma; M Maeda; Y Kumahara
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

9.  Identifying cancer relapse using SEER-Medicare data.

Authors:  Craig C Earle; Ann B Nattinger; Arnold L Potosky; Kathleen Lang; Rajiv Mallick; Mark Berger; Joan L Warren
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

10.  The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer.

Authors:  N Fersht; L Vini; R A'Hern; C Harmer
Journal:  Thyroid       Date:  2001-12       Impact factor: 6.568

View more
  15 in total

Review 1.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Trends and Predictors of Chemotherapy Use among Thyroid Cancer Patients in the National Cancer Database (2004-2013).

Authors:  Stacey A Fedewa; Ahmedin Jemal; Amy Y Chen
Journal:  Eur Thyroid J       Date:  2016-10-21

Review 4.  Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.

Authors:  Masahiro Sugawara; Tran Ly; Jerome M Hershman
Journal:  Horm Cancer       Date:  2012-08-04       Impact factor: 3.869

5.  Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.

Authors:  Andries H Groen; Thomas H Beckham; Thera P Links; Debra A Goldman; Eric J Sherman; Michael M Tuttle; Hendrik P Bijl; Richard J Wong; John Th M Plukker; Nancy Y Lee
Journal:  J Surg Oncol       Date:  2019-11-16       Impact factor: 3.454

6.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

Review 7.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

8.  Evaluation of Survival and Postoperative Radiation Among Patients with Advanced Medullary Thyroid Carcinoma: An Analysis of the National Cancer Database.

Authors:  Thomas J Ow; Vikas Mehta; Seokhwa Kim; Mayand Vakil; Patricia Friedmann; Haejin In
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

Review 9.  Cabozantinib for progressive metastatic medullary thyroid cancer: a review.

Authors:  Joshua R Colombo; Richard O Wein
Journal:  Ther Clin Risk Manag       Date:  2014-05-28       Impact factor: 2.423

10.  Putative BRAF activating fusion in a medullary thyroid cancer.

Authors:  Katayoon Kasaian; Sam M Wiseman; Blair A Walker; Jacqueline E Schein; Martin Hirst; Richard A Moore; Andrew J Mungall; Marco A Marra; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.